IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference
IGM Biosciences, a clinical-stage biotechnology company focused on IgM antibodies, announced that CEO Fred Schwarzer will participate in a virtual fireside chat at the Bank of America Biotech SMID Cap Conference on December 8, 2022, at 2:45 p.m. EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IGM Biosciences, a clinical-stage biotechnology company focused on IgM antibodies, announced that CEO Fred Schwarzer will participate in a virtual fireside chat at the Bank of America Biotech SMID Cap Conference on December 8, 2022, at 2:45 p.m. EST.
The event will be webcast live on the company’s website, with a replay available for 90 days. IGM is dedicated to developing innovative therapies for cancer and other diseases, leveraging its IgM antibody technology, which offers superior binding capabilities compared to traditional antibodies.
Details
News Market Reaction – IGMS
The recorded move for IGMS in the trading session of this news was -4.59%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a virtual fireside chat at the Bank of America Biotech SMID Cap Conference on Thursday, December 8, 2022 at 2:45 p.m. EST.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About IGM Biosciences, Inc.
IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer, infectious diseases and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology and immunology and inflammation targets. For more information, please visit www.igmbio.com.
Contact
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.